National Research Act (1974)

National Research Act (1974)
Name	National Research Act
Enacted	1974
Citation	Pub.L. 93–348
Signed by	President Richard Nixon
Date signed	1974-07-12
Purpose	Protection of human subjects in biomedical and behavioral research
Related legislation	Public Health Service Act; Common Rule; Food and Drug Act

Contents

National Research Act (1974) The National Research Act (1974) established a statutory framework for human subjects protections, mandating review mechanisms and creating a federal commission to articulate ethical principles for research involving humans. It emerged amid public controversy over studies such as Tuskegee syphilis experiment, prompting policymakers including Senator Edward Kennedy, Representative Olin Teague, and executives from the Department of Health, Education, and Welfare to act. The Act influenced agencies like the National Institutes of Health, Food and Drug Administration, and institutions such as Harvard University, Johns Hopkins University, and Massachusetts Institute of Technology in developing oversight systems.

Background and Legislative History

Congress passed the Act following media and legal scrutiny of cases such as Tuskegee syphilis experiment, Willowbrook State School investigations, and critiques by Henry Beecher in his article on unethical research practices; hearings involved figures from National Academy of Sciences, American Medical Association, American Psychological Association, and advocacy by National Association for the Advancement of Colored People. Legislative deliberations referenced precedent statutes like the Hippocratic Oath debates, reports from the Advisory Committee on Human Radiation Experiments, and testimony from researchers at University of Pennsylvania, Columbia University, and University of California, Berkeley. Sponsors coordinated with committees chaired by members of United States Senate Committee on Labor and Public Welfare and United States House Committee on Interstate and Foreign Commerce to craft provisions responsive to public scandals highlighted by journalists at The New York Times, The Washington Post, and activists linked to Black Panthers and civil rights leaders such as Jesse Jackson.

The statute required institutions receiving federal funds from agencies including the National Institutes of Health, National Science Foundation, and Department of Defense to establish review mechanisms and comply with standards influenced by documents like the Nuremberg Code and international instruments such as the Declaration of Helsinki. Core mandates addressed informed consent procedures tied to court decisions like Schloendorff v. Society of New York Hospital and governance expectations reflecting practices at Mayo Clinic and Cleveland Clinic. The Act also specified funding priorities that affected research at centers such as Fred Hutchinson Cancer Research Center and influenced training programs at Stanford University and University of Michigan.

The Act created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, staffed by appointees drawn from fields represented by institutions including Johns Hopkins University School of Medicine, Columbia University Medical Center, Georgetown University, and advocates from organizations such as American Civil Liberties Union and Pew Charitable Trusts. The Commission produced seminal guidance and convened experts from World Health Organization, Centers for Disease Control and Prevention, American Association for the Advancement of Science, and ethicists associated with Case Western Reserve University and Yale University. Its reports engaged debates connected to legal opinions from the Supreme Court of the United States and influenced policy decisions at Veterans Health Administration and National Cancer Institute.

Implementation led to widespread establishment of Institutional Review Boards at universities and hospitals including Brigham and Women's Hospital, University of Chicago, and University of Pennsylvania Health System, modeled after advisory bodies in institutions like Rockefeller University and Salk Institute. IRBs adopted procedures resonant with practices at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and systems in place at Veterans Affairs facilities. The IRB model affected contract research organizations working with pharmaceutical companies such as Merck & Co., Pfizer, and GlaxoSmithKline, and reshaped interactions with biotechnology firms like Genentech and academic medical centers including Mount Sinai Health System.

The National Commission drafted the Belmont Report articulating principles of respect for persons, beneficence, and justice, building upon moral philosophy from thinkers cited at conferences hosted by Kennedy Institute of Ethics, Princeton University, University of Chicago Law School, and ethics programs at Georgetown University. The Belmont framework guided policy at federal programs such as Indian Health Service and informed institutional policies at Boston Children's Hospital, UCLA Medical Center, and Mayo Clinic Proceedings. Its influence extended to international research norms discussed at United Nations forums and regulatory harmonization efforts with agencies like the European Medicines Agency.

Enforcement mechanisms evolved through regulations promulgated by agencies including the Department of Health and Human Services, Food and Drug Administration, and guidance under the Common Rule; subsequent amendments and clarifications involved input from bodies such as the National Institutes of Health, Office for Human Research Protections, Presidential Commission for the Study of Bioethical Issues, and stakeholders from academia like University of California, San Francisco and Duke University Medical Center. Legal challenges and judicial review referenced cases in federal courts including the United States Court of Appeals for the D.C. Circuit and policy shifts traced to executive actions by administrations of Jimmy Carter, Ronald Reagan, Bill Clinton, and Barack Obama. Contemporary debates continue to involve private research sponsors such as Johnson & Johnson and global partners like World Health Organization in adapting protections to genomics research at Broad Institute, data-driven studies at Google and Microsoft Research, and multisite trials coordinated by networks like ClinicalTrials.gov.